Clinical trials
Multiple myeloma clinical trials
A cancer of plasma cells in the bone marrow that affects the blood and bones. We’re tracking 552 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05970198Recruiting
Radiation with helical tomotherapy before stem cell transplant
This trial studies a specific type of radiation (helical tomotherapy) in people with multiple myeloma who are planning an autologous stem cell transplant. It may help the study team understand how safe and effective this approach is when used during transplant preparation.
Wuhan, HubeiAges 18–75 - NCT05972135RecruitingPhase 2
Outpatient injections for multiple myeloma with teclistamab or talquetamab
This Phase 2 trial tests two antibody medicines (teclistamab or talquetamab) given as outpatient injections, to treat multiple myeloma. It also tests preventing and treating side effects with supportive medicines, aiming to improve disease control in people who have already tried other myeloma treatments.
Tucson, ArizonaAges 18 years+ - NCT05996367Recruiting
Single radiation dose for painful myeloma bone lesions
This trial is testing whether a single dose of radiation can effectively relieve bone pain caused by multiple myeloma. It is designed for people who have a painful bone lesion and are stable on or off treatment.
São Paulo, São PauloAges 18–85 - NCT06039735Recruiting
Heart ultrasound study in multiple myeloma treated with RVd
This study looks at how a new heart ultrasound test can measure heart side effects and overall outcomes in people with multiple myeloma who are treated with the RVd drug combination. It may help doctors better understand heart risks during treatment.
Jinan, ShandongAges 18–70 - NCT06048250RecruitingPhase 1
Mezigdomide after Abecma for multiple myeloma
This trial tests a new drug called mezigdomide (CC-92480) for people with multiple myeloma who have already received the CAR T-cell therapy Abecma. The goal is to see if mezigdomide can help keep the cancer under control after Abecma.
Duarte, CaliforniaAges 18 years+ - NCT06055894Recruiting
Plant-based diet and supplements for smoldering myeloma or MGUS
This study tests whether a plant-based diet and certain supplements can help people with smoldering multiple myeloma (SMM) or monoclonal gammopathy of undetermined significance (MGUS). Participants will learn to cook plant-based recipes and track their meals using a phone app.
Basking Ridge, New JerseyAges 18 years+ - NCT06083207RecruitingPhase 1/Phase 2
IBI3003 for multiple myeloma that has returned or not responded
This trial tests an investigational drug called IBI3003 in people with multiple myeloma that has come back or hasn't responded to previous treatments. The goal is to see if it is safe and effective.
Wollongong, New South WalesAges 18 years+ - NCT06105554RecruitingPhase 1/Phase 2
Study of belumosudil for relapsed or refractory multiple myeloma
This trial tests a new drug called belumosudil, alone or with dexamethasone, for people with multiple myeloma that has come back or stopped responding to at least three prior treatments. The goal is to see if it can help when other therapies have stopped working.
Houston, TexasAges 18 years+ - NCT06107738RecruitingPhase 2
Iberdomide and Daratumumab after stem cell transplant for multiple myeloma
This trial tests two medicines, iberdomide and daratumumab, given as maintenance therapy after an autologous stem cell transplant. It is for people with multiple myeloma who still have small amounts of cancer cells detected after transplant and who have already been treated with a daratumumab-containing regimen.
Detroit, MichiganAges 18 years+ - NCT06115135RecruitingPhase 2
Venetoclax with isatuximab and dexamethasone for myeloma
This trial tests a combination of three drugs (venetoclax, isatuximab, and dexamethasone) for people with multiple myeloma that has come back or stopped responding to earlier treatments. It is for patients whose cancer cells have a specific genetic change, called t(11;14).
West Hollywood, CaliforniaAges Any age - NCT06119685RecruitingPhase 1/Phase 2
IDP-023 alone or with other antibodies for blood cancers
This trial tests an experimental drug, IDP-023, given alone or with antibody therapies for people with advanced blood cancers like multiple myeloma or non-Hodgkin lymphoma that have not responded to previous treatments. The goal is to see if it can shrink tumors or slow the disease.
Los Angeles, CaliforniaAges 18 years+ - NCT06132711RecruitingPhase 1/Phase 2
CAR-T therapy for relapsed multiple myeloma
This trial tests a new kind of CAR-T cell therapy (called APRIL-BAFF-Bicephali CAR-T) for people with multiple myeloma that has come back or not responded to treatment. It aims to see if this therapy is safe and can help when other treatments have stopped working.
Xuzhou, JiangsuAges 18–70 - NCT06138275RecruitingPhase 2
Elranatamab for relapsed multiple myeloma after Abecma
This trial tests a new drug called elranatamab for people with multiple myeloma that has come back or not responded to treatment, specifically after they have received a therapy named idecabtagene vicleucel (Abecma). It aims to see if elranatamab can help control the disease.
Boston, MassachusettsAges 18 years+ - NCT06140966RecruitingPhase 2
Daratumumab and Carfilzomib combo for high-risk multiple myeloma
This trial tests a combination of the drugs daratumumab, carfilzomib, lenalidomide, and dexamethasone given before and after a stem cell transplant for people with ultra high-risk multiple myeloma. The goal is to see if this regimen is safe and more effective than standard treatments.
Wuhan, HubeiAges 18–70 - NCT06145581Recruiting
Remote health coaching for older myeloma patients with fatigue
This study tests whether remote monitoring and health coaching can improve quality of life in older adults with multiple myeloma who are experiencing fatigue. You'll use a tablet or smartphone to track symptoms and get support from a coach.
Rochester, MinnesotaAges 65 years+ - NCT06149910Recruiting
Study of Treatment Plans for Newly Diagnosed Multiple Myeloma
This study looks at whether a new treatment plan (called a clinical pathway) helps doctors make better decisions for people just diagnosed with multiple myeloma. It will review medical records and may ask you to use a secure online platform to share your health information.
Seattle, WashingtonAges 18 years+ - NCT06158269RecruitingPhase 2
DVRd treatment for newly diagnosed double-hit myeloma
This trial tests a combination of four drugs (daratumumab, bortezomib, lenalidomide, and dexamethasone) for people newly diagnosed with a high-risk form of multiple myeloma called double-hit myeloma. It aims to see if this drug combo can improve outcomes for those with two or more high-risk genetic changes.
TianjinAges 18–70 - NCT06158412RecruitingPhase 2
ATRA plus KPD for relapsed or refractory multiple myeloma
This trial tests a combination of all-trans retinoic acid (a form of vitamin A) with a chemotherapy regimen called KPD for patients whose multiple myeloma has come back or is not responding to standard treatments. The goal is to see if this combination can help control the disease.
Xiamen, FujianAges 18 years+ - NCT06158841RecruitingPhase 3
Etentamig vs standard therapy for relapsed myeloma
This trial tests a new IV treatment called etentamig compared to standard therapies for people with multiple myeloma that has come back or stopped responding. It may be an option if you've already tried at least two different treatments, including common drug classes.
Birmingham, AlabamaAges 18 years+ - NCT06182774RecruitingPhase 3
Fixed vs ongoing treatment for older adults with new myeloma
This trial compares stopping treatment after a set number of cycles versus continuing it for people over 65 or those who cannot have a stem cell transplant. It tests whether a fixed treatment period works as well as long-term treatment for newly diagnosed multiple myeloma.
Edmonton, AlbertaAges 18 years+ - NCT06183489RecruitingPhase 2
Elranatamab for high-risk smoldering multiple myeloma
This trial tests a new drug called Elranatamab for people with a high-risk form of smoldering multiple myeloma (SMM). The goal is to see if the drug can prevent or delay the progression to active multiple myeloma.
HelsinkiAges 18 years+ - NCT06185751RecruitingPhase 1
Testing CS1 CAR-T for multiple myeloma
This study tests a new cell therapy called CS1 CAR-T, which helps your immune system attack myeloma cells that still grow after several other treatments. It's for people who have already tried at least three different types of therapy.
St Louis, MissouriAges 18 years+ - NCT06207799RecruitingPhase 2
Drug combo before and after transplant for high-risk myeloma
This trial tests a two-step approach for people with newly diagnosed, high-risk multiple myeloma who are eligible for a stem cell transplant. You'll get a drug called elranatamab before transplant to 'purge' the cancer, and then after transplant, you'll get maintenance therapy guided by how well your cancer is controlled. The goal is to see if this reduces the chance of the cancer coming back.
Houston, TexasAges 18–75 - NCT06209606RecruitingEarly Phase 1
Blood test study for multiple myeloma progression
This study is testing whether a blood test that measures a protein called BCMA can help doctors know if your multiple myeloma is getting worse. You may be able to join if your myeloma has come back or not responded to at least two prior treatments, and you have not taken the drug Ruxolitinib before.
West Hollywood, CaliforniaAges 18 years+
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for multiple myeloma?
- Yes. Clin2 currently lists 552 recruiting multiple myeloma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a multiple myeloma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.